Kimihiro Ito

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 198 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

Noboru Shinkai, Yasuhito Tanaka, E ORITO et al. · Hepatology Research · 2006 · 71 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms

Kimihiro Ito, Makoto Mitsunaga, Seiji Arihiro et al. · BMC Cancer · 2016 · 49 citations · Full text

Medicine, Oncology, Pharmacology +15

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <i>In Vivo</i> Antitumor Properties and a Favorable Tolerability Profile

Hidenori Fujita, Kazutaka Miyadera, Masanori Kato et al. · Molecular Cancer Therapeutics · 2013 · 37 citations

Medicine, Oncology, Pharmacology +17

Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging

Kimihiro Ito, Makoto Mitsunaga, Takashi Nishimura et al. · Oncotarget · 2016 · 37 citations · Full text

Medicine, Immunology, Oncology +17